DB:GTU2

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Oncternal Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GTU2 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

4.3%

GTU2

0.5%

DE Biotechs

2.6%

DE Market


1 Year Return

-37.1%

GTU2

-4.1%

DE Biotechs

8.1%

DE Market

Return vs Industry: GTU2 underperformed the German Biotechs industry which returned -4.1% over the past year.

Return vs Market: GTU2 underperformed the German Market which returned 8.1% over the past year.


Shareholder returns

GTU2IndustryMarket
7 Day4.3%0.5%2.6%
30 Day8.9%-3.9%0.6%
90 Day8.0%-0.4%11.5%
1 Year-37.1%-37.1%-3.9%-4.1%10.5%8.1%
3 Yearn/a24.0%23.4%6.3%-2.1%
5 Yearn/a19.6%17.6%15.2%-0.3%

Price Volatility Vs. Market

How volatile is Oncternal Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oncternal Therapeutics undervalued compared to its fair value and its price relative to the market?

4.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GTU2's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GTU2's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GTU2 is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: GTU2 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GTU2's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GTU2 is overvalued based on its PB Ratio (4.1x) compared to the DE Biotechs industry average (2.2x).


Next Steps

Future Growth

How is Oncternal Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

62.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oncternal Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Oncternal Therapeutics performed over the past 5 years?

30.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: GTU2 is currently unprofitable.

Growing Profit Margin: GTU2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if GTU2's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare GTU2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTU2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.4%).


Return on Equity

High ROE: GTU2 has a negative Return on Equity (-185.87%), as it is currently unprofitable.


Next Steps

Financial Health

How is Oncternal Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GTU2's short term assets ($16.6M) exceed its short term liabilities ($7.3M).

Long Term Liabilities: GTU2's short term assets ($16.6M) exceed its long term liabilities ($53.0K).


Debt to Equity History and Analysis

Debt Level: GTU2 is debt free.

Reducing Debt: GTU2 had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTU2 has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: GTU2 is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Oncternal Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GTU2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GTU2's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GTU2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTU2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GTU2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Jim Breitmeyer (66 yo)

no data

Tenure

US$1,115,838

Compensation

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph.D., serves as Director of Otonomy, Inc. since June 20, 2018. He serves as the Chief Executive Officer and President of Oncternal Therapeutics, Inc. Dr. ...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.12M) is above average for companies of similar size in the German market ($USD476.02K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James Breitmeyer
Presidentno dataUS$1.12m1.4%
$ 666.6k
Hazel Aker
General Counsel1.58yrsUS$929.92k0.26%
$ 122.7k
Frank Hsu
Chief Medical Officer1yrUS$1.33mno data
Richard Vincent
CFO, Treasurer & Secretary3.25yrsno data0.24%
$ 112.8k
Gunnar Kaufmann
Chief Scientific Officer0.92yrno datano data
Rajesh Krishnan
Senior Vice President of Chemistry1yrno datano data
Igor Bilinsky
Chief Business Officer0.92yrno datano data

1.0yrs

Average Tenure

57.5yo

Average Age

Experienced Management: GTU2's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
James Breitmeyer
Presidentno dataUS$1.12m1.4%
$ 666.6k
Michael Carter
Independent Director1.58yrsUS$146.03k0.0026%
$ 1.2k
Daniel Kisner
Independent Director1.58yrsUS$148.58k0.050%
$ 23.9k
William LaRue
Independent Director1.58yrsUS$148.30k0.082%
$ 39.3k
David Hale
Independent Chairman1.58yrsUS$272.80kno data
Thomas Kipps
Scientific Advisorno datano datano data
Charles Theuer
Independent Director2.25yrsUS$143.77k0.074%
$ 35.1k
Man Cho
Independent Director0.67yrUS$89.71kno data
Robert Wills
Non-Independent Director1.17yrsUS$484.31kno data
Jeffrey Toretsky
Scientific Advisorno datano datano data
Xin Nakanishi
Independent Director2.58yrsUS$141.50kno data

1.6yrs

Average Tenure

66yo

Average Age

Experienced Board: GTU2's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GTU2 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.6%.


Top Shareholders

Company Information

Oncternal Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncternal Therapeutics, Inc.
  • Ticker: GTU2
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$56.168m
  • Listing Market Cap: US$47.653m
  • Shares outstanding: 19.92m
  • Website: https://www.oncternal.com

Number of Employees


Location

  • Oncternal Therapeutics, Inc.
  • 12230 El Camino Real
  • Suite 300
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 2019
GTU2DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2019

Biography

Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company’s product pipeline includes cirmtuzumab, a monoclonal anti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/08 21:12
End of Day Share Price2020/08/07 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.